Active matrix metalloproteinase-2 activity discriminates colonic mucosa, adenomas with and without high-grade dysplasia, and cancers.
Pathologic assessment of colorectal adenomas, a complex task with significant interobserver variability, typically defines the scheduling of surveillance colonoscopies after removal of adenomas. We have characterized the activity levels of pro-matrix metalloproteinase-2, active matrix metalloproteinase-2, and matrix metalloproteinase-9 in colorectal adenomas and carcinomas as potential markers of pathologic progression during colorectal tumorigenesis. Endogenous fully activated matrix metalloproteinase-2, in particular, has been studied less frequently in adenomas due to difficulties in detection. For this report, tissues (n = 119) from 51 individuals were extracted and assayed on gelatin zymograms with digital standardization to nanogram quantities of purified active controls. Resulting data were assessed by graphical and multinomial logit regression analyses to test whether matrix metalloproteinase-2 or matrix metalloproteinase-9 activities could discriminate among 4 different types of colorectal tissue (normal mucosa, adenomas with or without high-grade dysplasia, and invasive carcinomas). Active matrix metalloproteinase-2 successfully discriminated among these tissue categories. Median activity for active matrix metalloproteinase-2 increased in a stepwise fashion with pathologic progression from normal mucosa to adenoma without high-grade dysplasia to adenoma with high-grade dysplasia to cancer. Although pro-matrix metalloproteinase-2 and pro-matrix metalloproteinase-9 activities could discriminate to some extent among tissue categories, those effects did not contribute additional information. Active matrix metalloproteinase-2 activity correlated significantly with histopathologic assessment of colorectal tissues. The ability of active matrix metalloproteinase-2 to distinguish adenomas with high-grade dysplasia from adenomas without high-grade dysplasia may be particularly useful in predicting future colorectal cancer risk for an individual, thus optimizing scheduling of surveillance colonoscopies.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA. mmurnane@bu.edu
Mary Jo
MJ
Murnane
Jinguo
J
Cai
Sania
S
Shuja
David
D
McAneny
John B
JB
Willett
D000236:Adenoma / Q000201:enzymology / Q000473:pathology*; D011125:Adenomatous Polyposis Coli / Q000201:enzymology / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003106:Colon / Q000166:cytology* / Q000201:enzymology; D015179:Colorectal Neoplasms / Q000201:enzymology / Q000473:pathology*; D003937:Diagnosis, Differential; D018450:Disease Progression; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000166:cytology* / Q000201:enzymology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D008875:Middle Aged; D055815:Young Adult
D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
In Vivo. 1997 May-Jun;11(3):209-16
9239513
J Biol Chem. 1995 Mar 10;270(10):5331-8
7890645
Matrix Biol. 2007 Oct;26(8):587-96
17669641
Gastroenterology. 2002 Oct;123(4):1109-19
12360473
Mol Carcinog. 1994 Aug;10(4):199-206
8068180
Dig Dis Sci. 2002 Aug;47(8):1821-30
12184536
Arch Biochem Biophys. 1997 Jun 15;342(2):261-74
9186487
Biochem Biophys Res Commun. 1982 Aug 31;107(4):1173-8
6291522
Br J Cancer. 2000 Jul;83(2):215-8
10901373
Gastroenterology. 2006 May;130(6):1872-85
16697750
FEBS Lett. 2007 Jul 10;581(17):3303-10
17597617
Ann Surg. 2001 Jun;233(6):786-92
11371737
Am J Gastroenterol. 2008 Jun;103(6):1331-3
18547221
Br J Cancer. 1998 Dec;78(11):1495-502
9836483
Dig Dis Sci. 2006 Nov;51(11):2068-72
17009118
Dis Colon Rectum. 2002 Apr;45(4):537-43
12006939
Pathol Oncol Res. 2008 Mar;14(1):31-7
18347934
Anal Biochem. 1994 May 1;218(2):325-9
8074288
Biochim Biophys Acta. 1996 Apr 16;1293(2):259-66
8620038
Biol Chem. 1996 Jul-Aug;377(7-8):529-33
8922288
Surg Oncol. 2009 Mar;18(1):31-50
18672360
Int J Colorectal Dis. 2007 Oct;22(10):1165-72
17394006
Am J Gastroenterol. 2008 Jun;103(6):1329-31
18547220
Dis Colon Rectum. 2000 Mar;43(3):389-95
10733122
J Biol Chem. 2005 Mar 11;280(10):9291-6
15615702
Am J Gastroenterol. 2008 Jun;103(6):1327-9
18547218
J Mol Diagn. 2008 Jan;10(1):13-27
18165277
J Biol Chem. 2004 Mar 5;279(10):8592-601
14681236
Cancer Res. 1993 May 15;53(10 Suppl):2208-11
8485704
Mol Carcinog. 1997 Aug;19(4):225-9
9290698
Nat Rev Cancer. 2001 Oct;1(1):55-67
11900252
J Biol Chem. 2000 Aug 25;275(34):26416-22
10827176
Br J Surg. 2000 Sep;87(9):1215-21
10971431
J Biol Chem. 2000 Aug 25;275(34):26411-5
10827175
J Biol Chem. 2006 Apr 14;281(15):10337-46
16469749
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):101-17
15000152
J Biol Chem. 2001 Dec 14;276(50):47402-10
11584019
J Biol Chem. 2000 Apr 21;275(16):12080-9
10766841
J Histochem Cytochem. 1973 Dec;21(12):1066-81
4587225
J Biol Chem. 1951 Nov;193(1):265-75
14907713
Int J Cancer. 2009 Dec 15;125(12):2893-902
19551856
Eur J Cancer. 2006 Dec;42(18):3246-52
16973348
Biochem J. 1995 Jun 1;308 ( Pt 2):645-51
7772054